DALLAS, TX / ACCESSWIRE / March 27, 2020 / CerSci Therapeutics (“CerSci”), a non-opioid pain relief drug development company based in Dallas, Texas today announced that Dr. Lucas Rodriguez, Chief Executive Officer plans to present an overview of the company and provide a business update at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. During the 25 minute presentation, participants will be able to submit questions electronically. Details are as follows:
Date/Time: Tuesday, March 31, 2020 at 1:30 p.m. EDT
To access the presentation, please login HERE
Webcast archive: 24 hours following the presentation an archive of the event will be available on the Company’s website at www.cersci.com
About CerSci Therapeutics
CerSci is a clinical-stage pharmaceutical company developing non-opioid analgesic drug products without the deleterious side effects (e.g., abuse liability, cognitive impairment, respiratory depression, etc.) of current pain treatments on the market. CerSci’s lead candidate, CT-044, is a novel, orally bioavailable compound that will initially target post-operative and chronic neuropathic pain indications.
Investor Relations Contact:
Chiara Russo
Solebury Trout
+617-221-9197
crusso@soleburytrout.com
SOURCE: CerSci Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/582880/CerSci-Therapeutics-to-Present-at-the-Upcoming-2020-Solebury-Trout-Virtual-Global-Healthcare-Conference-Series
Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St.…
Strategic elevation signals bold expansion as Doceree redefines healthcare marketing with AI-powered precision and purposeSHORT…
Next-generation EMR platform recognized for helping specialty practices deliver efficient, personalized patient careSAN FRANCISCO, Feb.…
Agentic AI integrates EHR and RTLS data to automate equipment workflows and improve operational efficiency,…
PUNE, India, Feb. 4, 2026 /PRNewswire/ -- For nearly a decade, robotic surgery was sold as progress.…
Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked…